Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AnaptysBio, Inc., Arrowhead Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Latest Biotechnology and AnaptysBio, Inc., Arrowhead Pharmaceuticals, Inc. Stock News

As of April 15, 2026, AnaptysBio, Inc. had a $2.0 billion market capitalization, compared to the Biotechnology median of $281.9 million. AnaptysBio, Inc.’s stock is up 38.1% in 2026, down 2.3% in the previous five trading days and up 295.4% in the past year.

Currently, AnaptysBio, Inc. does not have a price-earnings ratio. AnaptysBio, Inc.’s trailing 12-month revenue is $234.6 million with a -5.6% net profit margin. Year-over-year quarterly sales growth most recently was 151.0%. Analysts expect adjusted earnings to reach $-4.076 per share for the current fiscal year. AnaptysBio, Inc. does not currently pay a dividend.

As of April 15, 2026, Arrowhead Pharmaceuticals, Inc. had a $9.9 billion market cap, putting it in the 78th percentile of all stocks. Arrowhead Pharmaceuticals, Inc.’s stock is up 2.5% in 2026, up 2.7% in the previous five trading days and up 501.78% in the past year.

Currently, Arrowhead Pharmaceuticals, Inc.’s price-earnings ratio is 48.1. Arrowhead Pharmaceuticals, Inc.’s trailing 12-month revenue is $1.1 billion with a 18.5% net profit margin. As of April 15, 2026, Arrowhead Pharmaceuticals, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-3.239 per share for the current fiscal year. Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
AnaptysBio, Inc.	ANAB	F
Arrowhead Pharmaceuticals, Inc.	ARWR	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

AnaptysBio, Inc. has a Value Score of 14, which is Ultra Expensive. Arrowhead Pharmaceuticals, Inc. has a Value Score of 8, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither AnaptysBio, Inc., Arrowhead Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if AnaptysBio, Inc., Arrowhead Pharmaceuticals or Inc. is the better investment when it comes to value.

AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
AnaptysBio, Inc.	ANAB	A
Arrowhead Pharmaceuticals, Inc.	ARWR	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

AnaptysBio, Inc. has a Quality Score of 87, which is Very Strong. Arrowhead Pharmaceuticals, Inc. has a Quality Score of 77, which is Strong.

The Quality Grade Winner: AnaptysBio, Inc.

As you can clearly see from the Quality Grade breakdown above, AnaptysBio, Inc. has a better overall quality grade than Arrowhead Pharmaceuticals, Inc.. For investors who are looking for companies with higher quality than others in the same industry, AnaptysBio, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
AnaptysBio, Inc.	ANAB	C
Arrowhead Pharmaceuticals, Inc.	ARWR	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

AnaptysBio, Inc. has a Earnings Estimate Score of 45, which is Neutral. Arrowhead Pharmaceuticals, Inc. has a Earnings Estimate Score of 46, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither AnaptysBio, Inc., Arrowhead Pharmaceuticals or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if AnaptysBio, Inc., Arrowhead Pharmaceuticals or Inc. is the better investment when it comes to estimate revisions.

Other AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc. Grades

In addition to Quality, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, AnaptysBio, Inc., Arrowhead Pharmaceuticals or Inc. Stock?

Overall, AnaptysBio, Inc. stock has a Value Score of 14, Estimate Revisions Score of 45 and Quality Score of 87.

Arrowhead Pharmaceuticals, Inc. stock has a Value Score of 8, Estimate Revisions Score of 46 and Quality Score of 77.

Comparing AnaptysBio, Inc., Arrowhead Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.